Autres langues Viracta Therapeutics, Inc.

Actions

VIRX

US92765F1084

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 18/04/2024			Varia. 5j.	Varia. 1 janv.
0,909 ^USD	-2,91 %		-22,31 %	+59,47 %

15/04	Viracta Therapeutics, Inc. annonce des résultats préliminaires positifs de la phase 1 de l'essai pivot de phase 2 NAVAL-1	CI
01/04	Viracta Therapeutics présentera les principaux résultats de l'étape 1 de l'essai NAVAL-1 de Nana-val au congrès annuel 2024 de la Société d'hématologie de Taïwan	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma	16/04
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma	15/04
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	15/04
Viracta Therapeutics : HST 2024 – Presentation	15/04
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01/04
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01/04
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	21/03
Viracta Therapeutics, Inc. Announces Executive Changes	20/03
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	20/03
North American Morning Briefing : Inflation -2-	15/03
Sunesis: Q4 Earnings Snapshot	07/03
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial	29/02
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Viracta Therapeutics, Inc. Provides Clinical Update	04/01
Viracta Therapeutics Provides Clinical Update and Outlook for 2024	04/01
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma	12/12
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels	04/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Viracta Therapeutics, Inc.

Actions

VIRX

US92765F1084

Autres langues

Filtres